Lorad scores deal with U.S. Surgical
Mammography vendor Lorad of Danbury, CT, has signed an exclusivemultiyear agreement with breast biopsy instrument supplier U.S.Surgical that could be worth up to $10 million to Lorad in thefirst year of the contract. Under the terms of the deal,
Mammography vendor Lorad of Danbury, CT, has signed an exclusivemultiyear agreement with breast biopsy instrument supplier U.S.Surgical that could be worth up to $10 million to Lorad in thefirst year of the contract. Under the terms of the deal, Loradwill supply stereotactic equipment such as its StereoGuide coreneedle biopsy system to U.S. Surgical for use with that company'sAdvanced Breast Biopsy Instrument (ABBI) system. ABBI employsa one-step procedure to both place a wire marker in the breastand remove a tissue specimen for biopsy.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
